Small Cap Feast
Small Cap Feast – 22 July 2019
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
El Oro (ELX) has been put into Voluntary liquidation due to winding up and reconstruction proposal.
El Oro (ELX) has been put into Voluntary liquidation due to winding up and reconstruction proposal.
What’s Cooking in the IPO Kitchen?
Interswitch, a Nigeria-based payments firm, has hired advisers to resurrect plans for a stock-market listing in London and Lagos later this year, which may value the financial technology company at $1.3 billion to $1.5 billion.
Main Market (Specialist Funds)
Voyager AIR The Company will focus on the acquisition, leasing and management of primarily widebody aircraft, with asset management services to be provided by Amedeo Limited the IPO will comprise a Placing and Offer for Subscription of Shares to raise up to approximately US$200m.
Roxi Music UK music streaming service plans London IPO as it goes up against Spotify. They have appointed investment bank Arden Partners for an initial public offering (IPO) on the London Stock Exchange later this year.
Freyherr International Group PLC the Medicinal Cannabis holding company established in 2016, is planning to list on the NEX exchange on the 30th July
Angle PLC (AGL) 71.50p £122m
ANGLE, a world-leading liquid biopsy company, announced that one of its leading customers, the Disseminated Cancer Cell Network (DCCNet), Duesseldorf, an interdisciplinary team of cancer researchers and clinicians, has published new results in a peer-reviewed journal of work done to develop a “robust, reliable and cost-efficient workflow” for enrichment of single circulating tumor cells (CTCs).
This has been published by the DCCNet at the University Hospital and Medical Faculty of the Heinrich-Heine University of Duesseldorf as a peer-reviewed publication in the journal Cancers and is available at https://angleplc.com/library/publications/.
The researchers combined use of the Parsortix® system with the micromanipulator CellCelector™ to enable single CTCs to be analysed individually to investigate the heterogeneity of the cancer. They were able to complete PCR-based gene expression analysis of single CTCs processed by Parsortix direct from the patient sample as well as from cells obtained from Parsortix and subsequently cultured outside the patient. This approach may facilitate complex therapeutic decision-making based on the CTC analysis.
The work was undertaken in breast cancer and was able to detect varying gene expression between the individual CTCs as well as demonstrating that changes in the patient’s HER-2 expression can be detected.
21st Century Tech (C21) 3.20p £2.94m
21st Century Technology, the specialist provider of integrated systems and software to the passenger transport markets, announced it has secured contract awards with West Midlands Combined Authority (WMCA), valued at approximately £0.8m.
The awards include works to enhance existing passenger information displays throughout Birmingham City centre, valued at £0.3m within the current year, and the installation of new passenger information displays and public Wi-Fi for the first of the new Sprint Bus Rapid Transit(BRT) corridors valued at £0.5m commencing in 2020.
In the current financial year, 21st Century will deliver upgraded technology to Birmingham City Centre passenger information totems, replacing orange-LED displays with new, multi-colour LEDs; believed to be the first of their kind deployed in the UK transport market.
The award also includes the provision of 21st Century’s integrated technology to the first tranche of the new contemporary design bus shelters, being deployed throughout the West Midlands, specifically for the Sprint BRT corridors; enhancing transport infrastructure in the region. As part of the works, which are due to commence in H1 2020, 21st Century will be installing advanced displays and communications technologies. The framework allows WMCA to select from a number of additional options for application in the shelters, which would see the value increase.
Galantas Gold Corp (GAL) 4.80p £14.38m
Galantas Gold reported progress at the Omagh gold mine. An access drive on the fourth (1060) level has intersected the Kearney vein ahead of schedule. The intersection shows strongly developed mineralization. The north and south faces of the vein were channel sampled. The average of the two channels was 8.35 g/t gold over an average true width of 2.65 metres.
The vein intersection is expected to allow in-vein development both north and south on the fourth (1060) level. Development on the fourth level is anticipated to produce increased feed tonnage to the processing plant, which produces a concentrate sold under an off-take contract.
Development on the third (1072) level continues southwards with gold grades within the expected range.
A drivage from the 1072 access has been taken northwards, in-vein, for approximately 40 metres (July 19, 2019). Mineralisation beyond the first 20 metres is currently excluded from the geological model, due to paucity of data. The mineralization was shown to be persistent and has been followed in an in-vein development.
Two channel samples taken across the face as the drivage was developed at 24.1m and 27.6m into the third level (1072) north development showed a grade of 6.2g/t gold and 16.3 g/t gold respectively, each with a true width of 3 metres.
Pembridge Resources (PERE) Suspended
Pembridge Resources announced that its subsidiary Minto Explorations Limited has signed an agreement with Sumitomo Canada Limited”, a subsidiary of Sumitomo Corporation to receive a working capital facility in connection with an off-take agreement for 55,000 tonnes of copper concentrate, to be produced by the Minto mine. The Advanced Payment and the Off-Take are part of a broader strategic relationship between Sumitomo and Pembridge, In addition the parties are working together towards finalising a pre-payment facility agreement.
The Off-Take is for 100% of the copper concentrate produced at the Minto mine delivered on a cost, insurance and freight (CIF) basis to a nominated Japanese port and shall remain in place until (i) 55,000 tonnes of copper concentrate delivered, or (ii) 31 Dec 2020, whichever is later.
The Advanced Payment shall be made by Sumitomo to Minto on a monthly basis, for 90% of the estimated value of concentrate produced that month with final payment due on delivery to Japan.
The Advanced Payment allows Minto to immediately monetise each month’s production, eliminating the historically large working capital requirements when the site is unable to transport concentrate owing to seasonal weather disruptions.
The Advance Payment is subject to interest payable of $3 month LIBOR plus 1.5% until Sumitomo has taken delivery of the concentrate in Japan.
Harvest Minerals Ltd (HMI) 4.80p £8.73m
Harvest Minerals, the fertiliser producer, provided an update on the status of its application for a full mining license for the Company’s Arapua Project, located in the heart of the Brazilian agricultural belt in Minas Gerais. Arapua is fully operational and producing KPFértil, a multi-nutrient direct application natural remineraliser product.
The Agência Nacional de Mineração (ANM), formerly the Departamento Nacional de Produção Mineral, has confirmed its acceptance of the Company’s Plano de Aproveitamento Econômico submitted by the Company in July 2018. In essence, the Company Plan is a Feasibility Study wherein the Company demonstrates that the Arapua project is technically and economically feasible. The confirmation of its acceptance of the Company Plan and its content is the final step in the ANM’s consideration of the Company’s application for a full mining license.
Dekeloil PLC (DKL) 3.05p £10.60m
Further to the announcement earlier today that AgDevCo Limited, a leading African agriculture sector impact investor, has agreed to provide a €7.2m loan to the Company, DekelOil, the West African focused agricultural company, announced that as one of the conditions to the AgDevCo Loan, AgDevCo intends to subscribe for 41,188,990 new ordinary shares of €0.0003367 each in the Company at an issue price of 3.27p per Ordinary Share, raising gross proceeds of approximately £1.35m (€1.5m). The AgDevCo Subscription Price is based on a 5% premium to the last 30 days volume weighted average price of the Ordinary Shares.
Shearwater Group PLC (SWG) 1.90p £41.45m
Shearwater Group, the organisational resilience group, announced that its group company Brookcourt Solutions has secured a multi-million pound contract with a leading FTSE 100 global financial institution for the provision of security and cyber security services.
Under the terms of the contract, Brookcourt Solutions has been commissioned to deliver renewed support for a critical part of the organisation’s global security infrastructure over a 3-year period. In addition, Brookcourt Solutions will also implement a security solution utilising technology partner software, which will help defend the financial institution and their clients against the increasing onslaught of advanced threats from the internet.
Belvoir Group PLC (BLV) 115p £40.18m
Belvoir, the UK’s largest property franchise, today announces that it has changed name from ‘Belvoir Lettings PLC’ to ‘Belvoir Group PLC’. The Board believes that ‘Belvoir Group PLC’ better recognises the Group’s strategic success in diversifying from a single franchisor of residential lettings agents, to a multi franchisor, operating three property franchises offering residential sales and lettings, and a network of financial advisers offering mortgage and other property related financial services.
The change of name was executed by a resolution of the Board on 5 July 2019 as permitted under the Company’s Articles of Association and has been registered at Companies House and accordingly the change is now effective. The Company’s TIDM ‘BLV’ and ISIN ‘GB00B4QY1P51’ will both remain unchanged.
Ergomed plc (ERGO) 319p £139m
Ergomed, a provider of specialised services to the pharmaceutical industry, announced a trading update for the first half of 2019. The Company will provide further details of its first half performance with its interim results in Sept 2019.
Summary – trading ahead of expectations
Following a strong first half of the year, and the upgrade to market expectations in May 2019, Ergomed expects both revenue and EBITDA for the year ending 31 Dec 2019 to be ahead of current market expectations.
Ingenta PLC (ING) 67.50p £11.42m
Ingenta, a leading provider of innovative content solutions, announced that it has secured two further new deals for its Commercial software platform. These sales are for customers based in the UK and France and comprise the Ingenta Commercial Order to Cash, Contract Rights and Royalties, and Product Manager modules with scope for further services in due course. The combined implementation and licence deals are valued at £365K with total annual recurring fees of approximately £70K.
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email firstname.lastname@example.org with “unsubscribe me”.